From the MHRA Website:
"The guidance is intended to be a useful resource on the core elements
of a compliant data governance system across all GxP sectors (good
laboratory practice, good clinical practice, good manufacturing
practice, good distribution practice and good pharmacovigilance
It addresses fundamental failures identified by MHRA and international regulatory partners during GLP, GCP, GMP and GDP inspections; many of which have resulted in regulatory action."
Read more on the MHRA website.
Click here for the finalised guidance.